Ovarian ablation as a treatment for breast cancer

Surgical Oncology

Volumn 12, Issue 4, 2003, Pages 241-250

  Sainsbury, Richard ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; LhRH agonists; Ovarian ablation

Indexed keywords

ANTINEOPLASTIC AGENT; BUSERELIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN;

ALOPECIA; AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFECT; HOT FLUSH; HUMAN; INFECTION; NAUSEA; OVARIECTOMY; PRIORITY JOURNAL; REVIEW; VAGINAL DRYNESS;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIECTOMY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 1442311126     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2003.11.002     Document Type: Review

References (44)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma. suggestions for a new method of treatment, with illustrative cases Lancet. 2:1896;104-107.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. New England Journal of Medicine 1988;319:1681-92.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, Cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
6. Quinn M., Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. British Medical Journal. 311:1995;1391-1395.
7. Davidson N.E. Ovarian ablation as treatment for young women with breast cancer. Journal of National Cancer Institutional Monographs. 16:1994;95-99.
8. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., Hood N. Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology. 17:1999;2365-2370.
9. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 14:1996;1718-1729.
10. Dees E.C., Davidson N.E. Ovarian ablation as adjuvant therapy for breast cancer. Seminars in Oncology. 28:2001;322-331.
11. Pritchard K.I. Ovarian ablation as adjuvant therapy for early stage breast cancer. Cancer Treatment Researches. 94:1998;159-180.
12. Leung S.F., Tsao S.Y., Teo P.M., Choi P.H., Shiu W.C. Ovarian ablation failures by radiation. a comparison of two dose schedules British Journal of Radiology. 64:1991;537-538.
13. Furr B.J.A. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, 'Zoladex'. Hormonal Researches. 32(Suppl. 1):1989;86-92.
14. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 14:1996;1718-1729.
15. Koyama H., Wada T., Nishizawa Y.et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 39:1977;1403-1409.
16. Mehta R.R., Beattie C.W., Das Gupta T.K. Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Research and Treatment. 20:1992;125-132.
17. Poikonen P., Saarto T., Elomaa I.et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. European Journal of Cancer. 36:2000;43-48.
18. Del Mastro L., Venturini M., Sertoli M.R.et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients. prognostic role and clinical implications Breast Cancer Research and Treatment. 43:1997;183-190.
19. Pagani O., O'Neill A., Castiglione M.et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement. results of the international Breast Cancer Study Group (IBCSG) trial VI European Journal of Cancer. 34:1998;632-640.
20. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993;341:1293-8.
21. Jonat W. Luteinizing hormone-releasing hormone analogues - the rationale for adjuvant use in premenopausal women with early breast cancer. British Journal of Cancer. 78(Suppl. 4):1998;5-8.
22. Blamey R.W., Jonat W., Kaufmann M., Bianco A.R., Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. European Journal of Cancer. 28A:1992;810-814.
23. Taylor C.W., Green S., Dalton W.S., Martino S., Rector D., Ingle J.N.et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer. an intergroup study Journal of Clinical Oncology. 16:1998;994-999.
24. Jonat W., Kaufmann M., Sauerbrei W., Blamey R., Cuzick J., Namer I.et al. Goserelin versus CMF as adjuvant therapy in premenopausal patients with node-positive breast cancer. the ZEBRA study Journal of Clinical Oncology. 20:2002;2628-2635.
25. Untch M., Possinger K., Vasiljew L. First interim results of an ongoing study comparing the GNRH-agonist leuprorelin acetate and CMF as adjuvant treatment in premenopausal breast cancer. European Journal of Cancer. 34(Suppl. 5):1998;S20. (Abstract 80).
26. Schmid P., Untch M., Wallwiener D., Kosse V., Bondar G., Vassiljev L.et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients. preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin Acetate) Anticancer Researches. 22:2002;2325-2332.
27. Boccardo F., Rubagotti A., Amoroso D.et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian supression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients. results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial Journal of Clinical Oncology. 18:2000;2718-2727.
28. Jakesz R., Hausmaninger H., Samonigg H.et al. Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and -negative patients with hormone-responsive breast cancer. Breast. 10(Suppl. 1):2001;S10. (abstr S26).
29. Davidson N.E., O'Neill A., Vukov A. Effect of chemohormonal therapy in premenopausal, node-positive, receptor-positive breast cancer. an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101) Breast. 8:1999;232-233. (Abstract 069).
30. Davidson NE, O'Neill A, Vukov A, et al. Chemohormonal therapy in pre-menopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the ASCO 2003; Abstract 15.
31. Arriagada R, Le MG, Spielmann L, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Proceedings of the ASCO 2003.
32. Bianco A.R., Costanzo R., Di Lorenzo G., Adamo V., Altavilla G., D'Aprile M.et al. The MAM-1 GOCSI trial. a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node-positive (N+) early breast cancer (ebc) Proceedings of ASCO. 20:2001;27a. (Abstract 104).
33. Roche H.H., Kerbrat P., Bonneterre J., Fargeot P., Fumoleau P., Monnier A.et al. Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients (pts) with positive hormone receptor (HR+) and 1-3 node-positive tumor (N+), Results of the FASG 06 Trial. Proceedings of ASCO. 19:2000;72a. (Abstract 279).
34. Castiglione-Gertsch M., Gelber R.D., O'Neill A., Coates A.S., Goldhirsch A. Systemic adjuvant treatment for premenopausal node-negative breast cancer. European Journal of Cancer. 36:2000;549-550.
35. Castiglione-Gertsch M., O'Neill A., Gelber R.D., Nasi M.L., Rabaglio M., Lindtner J.et al. Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin? first results of the IBCSG trial VIII Proceedings of ASCO. 21:2002;38a. (Abstract 149).
36. Baum M., Houghton J., Odling-Smee W., Rutqvist L.E., Fornander T., Nordenskjold B.et al. Adjuvant Zoladex in premenopausal patients with early breast cancer. results from the ZIPP trial Breast. 10(Suppl. 1):2001;S32-S33. (Abstract P64).
37. Robert NJ, Wang M, Cella D, et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer <3 cm. Proceedings of ASCO 2003; 22: Abstract 16.
38. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 14:1996;1718-1729.
39. Cheung K., Forward D., Jackson L., Robertson J. The combined use of goserelin and anastrozole as second line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects. Proceedings of the ASCO. 20:2001;47b. (Abstract 1937).
40. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-39.
41. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. Journal of National Cancer Institute 2001;93:979-89.
42. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H-.J. Meeting Highlights. International Consensus Panel on the Treatment of Primary Breast Cancer Journal of Clinical Oncology. 19:2001;3817-3827.
43. Blamey R.W. Guidelines on endocrine therapy of breast cancer - EUSOMA. European Journal of Cancer. 38:2002;615-634.
44. Featherstone C.J., Harnett A.N., Brunt A.M., Johnson L. Methods of ovarian suppression used in the UK. The Breast. 11:2002;23-29.